glp-1r

GLP-1R Antagonist 1 is an orally active, CNS penetrant and non-competitive glucagon-like peptide 1 receptor (GLP-1R) antagonist (IC50: 650 nM).

VU0453379 is a highly selective, central nervous system-penetrant, positive allosteric modulator of glucagon-like peptide-1R (EC50: 1.3 μM).

GLP-1R Agonist DMB is an agonist of glucagon-like peptide 1 receptor (GLP-1R; KB = 26.3 nM for the recombinant human receptor).

GLP-1R agonist 25 (compound 13) is a GLP1-R agonist with an EC50 of 0.167 nM and is utilized in research for Type II diabetes.

Compound 1, also known as GLP-1R agonist 26, is an agonist of the glucagon-like peptide-1 receptor (GLP-1R) with an EC50 of <10 nM.

GLP-1R agonist 27 (compound 21) is a potent and orally active GLP-1R agonist. It enhances the accumulation of cyclic adenosine monophosphate (cAMP), reduces blood glucose levels, and decreases food intake. GLP-1R agonist 27 shows potential for research in obesity and type 2 diabetes mellitus (T2DM).

GLP-1R agonist 28 (Compound 19) is an orally active GLP-1R agonist that enhances insulin secretion and is applicable for research into GLP-1R-related disorders.

GLP-1R agonist 29 (Compound 20) is a GLP-1R agonist that induces hGLP-1R-mediated cAMP stimulation with an EC50 of 0.018 nM. It exhibits favorable pharmacokinetic properties and shows good in vivo exposure, with an AUC0-∞,sc of 77688 ng·h/mL.

GLP-1R agonist 30 is an orally active, selective GLP-1R agonist with an EC50 of 0.048 nM. It exhibits outstanding selectivity, with EC50 values exceeding 20 μM for GLP-2R, GIPR, and GCPR. GLP-1R agonist 30 significantly enhances cAMP stimulation and reduces hERG inhibition. The compound has good absorption and excellent β-arrestin pathway selectivity. Additionally, GLP-1R agonist 30 improves glucose tolerance and promotes insulin secretion in B-hGLP1R gene knock-in mice.

GLP-1R modulator L7-028 is a variant that enhances affinity for GLP-1 and (cAMP) signaling.

GLP-1R modulator C16 is a variable modulator that significantly increases the binding affinity of GLP-4.

GLP-1R modulator C5 is a small molecule GLP-1R orthosteric modulator that enhances GLP-1 binding to GLP-1R via transmembrane sites and can be used in the study of type II diabetes.

GLP-1R agonist 3 is a potent imidazole derivative and GLP-1R agonist with demonstrated research potential in diabetes. [Thickened]

GLP-1R agonist 8 is a potent GLP-1R agonist with an EC50 of less than 2 nM.

GLP-1R agonist 10 is a GLP-1 agonist (EC50: 0.051 nM).

GLP-1R agonist 1, a thickened imidazole derivative, is a potent agonist of GLP-1R with potential applications in diabetes research.

GLP-1R agonist 12 (Compound 123) is utilized in diabetes mellitus research as a glucagon-like peptide-1 receptor (GLP-1R) agonist.

GLP-1R agonist 17 is a potent GLP-1 receptor agonist with excellent efficacy in activating the GLP-1 receptor, primarily used in cardiovascular metabolic disease research.

GLP-1R agonist 9 acts as a GLP-1R agonist, demonstrating efficacy with EC50 values of 1.1 nM and 11 nM against CHO GLP-1R Clone H6 and Clone C6, respectively.

GLP-1R agonist 4, a potent agonist of GLP-1R, shows promise for diabetes research[1]. Acting on the principle of glucagon-like peptide-1 (GLP-1), a hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract, this compound holds potential therapeutic value.

GLP-1R agonist 14, also known as Compound 14, is a potent agonist of the GLP-1 receptor, demonstrating an EC50 range of 0-20 nM against human GLP-1 [1].

GLP-1R agonist 15 (Compound 101) is a GLP-1 receptor agonist [1].

Compound 115a, a GLP-1R agonist, effectively activates the GLP-1 receptor with an EC50 of 0.15 nM [1].

GLP-1R agonist 18 (example 117) acts as an agonist at GLP-1R, exhibiting an EC50 of 0.044 nM [1].